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ABSTRACT 
The linker histone H1 in mammals, involved in DNA packaging into chromatin, is 
represented by a family of variants. H1 tails undergo post-translational modifications 
(PTMs) that can be detected by mass spectrometry. We developed antibodies to analyse 
several of these as yet unexplored PTMs including the combination of H1.4 K26 
acetylation or trimethylation and S27 phosphorylation. H1.2-T165 phosphorylation was 
detected at S and G2/M phases of the cell cycle and was dispensable for chromatin 
binding and cell proliferation; while the H1.4-K26 residue was essential for proper cell 
cycle progression. We conclude that histone H1 PTMs are dynamic over the cell cycle 
and that the recognition of modified lysines may be affected by phosphorylation of 
adjacent residues.   
 
HIGHLIGHTS 
 Human histone H1.2 T165 is phosphorylated at S and G2/M phases of the cell 
cycle. 
 H1.2 T165 phosphorylation marks highly proliferative cancer cells. 
 H1.2 T165 is dispensable for cell proliferation and H1.2 binding to chromatin. 
 H1.4 S27 is phosphorylated at G2/M whether adjacent K26 is modified or not. 
 H1.4 K26 residue is required for cell proliferation and heterochromatin loading. 
 
*Highlights
1. INTRODUCTION 
The nucleosome core, which consists of 146 bp of DNA wrapped around an octamer of 
core histones, is the fundamental subunit of chromatin. In addition, histone H1 protein 
binds to linker DNA between two nucleosomes helping stabilize the chromatin fiber. In 
mammals, the H1 family includes up to eleven H1 variants that are either ubiquitous or 
tissue-specific. The reason for this remains unclear, but both their evolutionary 
conservation and significant differences in their amino acid sequence suggest that they 
are not functionally equivalent [1,2]. Given its role in the formation of higher-order 
chromatin structures, H1 has been classically seen as a structural component related to 
chromatin compaction. However, in recent years, the view that H1 plays a more 
dynamic role in regulating gene expression is gaining strength in the field, mostly due to 
H1 knock-out or knock-down studies in several organisms [3-8]. 
Among H1 variants, there are seven somatic H1 histones in human cells: H1.1 to H1.5 
are expressed in a replication-dependent manner, whereas H1.0 and H1X are 
replication-independent. H1.1 is restricted to certain tissues, H1.0 accumulates in 
terminally differentiated cells, and the rest are ubiquitously expressed. H1 histones are 
lysine-rich proteins presenting three domains: a short basic N-terminal tail, a highly 
conserved central globular domain and a long positively-charged C-terminal tail. The 
chromatin binding affinity and residence time is different between H1 subtypes due to 
differences mainly in the C-terminal tail, but also in the N-terminal tail [9-11]. 
Like core histones, linker histone H1 is post-translationally modified. According to the 
‘histone code’ hypothesis, histone post-translational modifications (PTMs) provide tools 
for altering chromatin structure, either modifying electrostatic interactions DNA-
histones or allowing recruitment of chromatin modifying enzymes [12]. With the 
development of mass spectrometry methods, some attempts to map H1 PTMs have been 
made in various species, showing that H1 is modified mainly by phosphorylation, but 
also by acetylation, methylation, ubiquitination, formylation and citrullination [13-19]. 
Certain H1 PTMs may modulate interactions with partners and could explain some 
reported specific functions of H1 variants. Only some of the aforementioned histone H1 
PTMs have been further analyzed in vivo.  
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Phosphorylation is the most well characterized modification of H1 histone and is tightly 
coupled to the cell cycle. The level of H1 phosphorylation progressively increases 
during the S phase, reaches its maximum from the late G2 phase into mitosis, and 
decreases rapidly in the telophase. Serine and threonine residues in both N- and C-
terminal tails are phosphorylated by cyclin-dependent kinases (CDKs) through the 
recognition of the (S/T)-P-X-(K/R) motif [13,20]. H1 phosphorylation in S phase 
promotes the DNA decondensation needed for replication, while phosphorylation in 
G2/M is involved in mitotic chromosome condensation. It has also been demonstrated 
that different H1.5 residues are phosphorylated at different cell cycle phases [21]. 
Furthermore, H1 is also phosphorylated by kinases other than CDKs. For instance, 
H1.4-S27, H1.4-S35 and H1.5-T10 phosphorylations are catalyzed by Aurora B kinase, 
protein kinase A (PKA), and glycogen synthase kinase-3 (GSK-3), respectively [22-24]. 
Interestingly, significantly higher levels of phosphorylated H1 have been observed in 
high-grade invasive bladder cancer cells compared with normal human bladder 
epithelial cells, in accordance with the greater proliferation capacity of cancer cells [25]. 
In agreement with the presence of H1 phosphorylation in the interphase nucleus, H1 
phosphorylation is also involved in gene regulation. For instance, H1 is phosphorylated 
before being displaced from the mouse mammary tumor virus promoter upon hormone 
induction [26]. Moreover, site-specific phosphorylation of histone H1 facilitates 
transcription by RNA polymerase I and II and has been implicated in ribosome 
biogenesis and control of cell growth [27]. 
H1 phosphorylation, together with methylation and acetylation, is also involved in 
heterochromatin formation by regulating HP1 binding. Lysine residue K26 on H1.4 is 
known to be both methylated and acetylated. G9a histone lysine methyltransferase 
mediates mono- and di-methylation, whereas JMJD2 reverses this modification [28]. 
Thus, HP1 binds specifically to methylated H1.4-K26, but the interaction is regulated 
by a ‘phospho-switch’ on the adjacent H1.4-S27 phosphorylation sites, and this prevents 
HP1 binding [29]. Moreover, histone deacetylase SirT1 interacts with H1 and 
deacetylates H1.4 at K26, regulating the formation of repressive heterochromatin [30]. 
Interestingly, G9a and Glp1 are also able to methylate H1.2-K187, but this methylation, 
which is stable during the cell cycle, cannot recruit HP1 and it is not reversed by 
JMJD2D [31]. 
Moreover, Kamieniarz et al. showed that H1.4-K34 acetylation by GCN5 is associated 
with promoters of active genes and regulatory regions. This modification seems to 
positively regulate transcription, both by increasing H1 mobility and by recruiting 
transcription factors [32]. Finally, histone H1 is also PARylated as a result of poly 
ADP-ribose polymerase (PARP-1) activity mediating H1 displacement from promoters 
and, consequently, leading to chromatin remodeling and transcription activation. In fact, 
PARP-1 and H1 are mutually exclusive in active promoters [33-36].  
These observations favor the view that specific modifications in linker H1 subtypes lead 
to them having specific functions in different processes. Thus, we decided to develop 
antibodies specifically recognizing some of the as yet uncharacterized H1 PTMs, among 
others: K17 acetylation, K26-S27 single and double modifications (acetylation or 
trimethylation, and phosphorylation), K46 ubiquitination and T165 phosphorylation, 
and we investigated the dynamics of these newly-described histone H1 PTMs. 
Recognition of all the modifications changed during the cell cycle due to the 
phosphorylation of Ser- or Thr-specific residues over the course of DNA replication and 
mitosis. As a consequence, the recognition intensity of neighboring acetylated or 
methylated Lys residues by specific antibodies decreased. We also investigated whether 
K26 and T165 residues were required for cell proliferation and proper loading of H1.4 
and H1.2, respectively, onto chromatin. Expression of a K26A mutant of H1.4 affected 
cell proliferation, gene expression and H1.4 stabilization in heterochromatin. Instead, 
H1.2-T165A showed no differences with respect to wild-type (WT) H1.2. Finally, 
H1.2-T165 phosphorylation was found to be a marker for proliferation and cancer 
malignancy. 
 
2. EXPERIMENTAL PROCEDURES 
2.1. Cell lines, mutagenesis and culture conditions 
Experiments were performed in the breast cancer-derived T47D-MTVL cell line or 
HeLa cells, or its derivative cells stably expressing hemagglutinin (HA)-tagged H1 
variants (H1-HA), or inducible shRNAs against H1 variants, described previously [7]. 
The mutagenesis of H1-HA was performed with the QuikChange Lightning Site-
Directed Mutagenesis Kit (Agilent). T47D and HeLa cells were grown in RPMI 1640 
medium and DMEM, respectively, supplemented with 10% FBS, 2 mM L-glutamine, 
100 U/ml penicillin, and 100 µg/ml streptomycin. Colcemid (Sigma) was added at 50 
ng/ml when indicated, and doxycycline (Sigma) was added at 2.5 mg/ml. Colon cancer 
cell lines HCT116, SW48, SW480, HCT15, LS147T, LS180 and Caco2 were grown in 
DMEM with 10% FBS (except for Caco2 for which 20% FBS was used). 
2.2. Cell cycle and proliferation analysis  
For cell cycle analysis, the cells were washed with cold PBS 1×, fixed in 70% ethanol 
and stained with a solution containing 3% Ribonuclease A (10 mg/ml, Sigma) and 3% 
solution A (38 mM sodium citrate, 500 µg/ml propidium iodide) in PBS 1×. Then, the 
samples were analyzed by fluorescence-activated cell sorting (FACS) using a FACS 
Calibur machine (BD Biosciences), CellQuest analysis software and the ModFit 
program. For cell proliferation analysis, the cells of interest expressing HA-tagged H1 
(GFP-positive) were mixed 1:1 with parental cells (GFP-negative) and cultured. Every 
three days, the cells were split and the percentage of cells that were GFP-positive was 
measured by FACS. 
2.3. Histone H1 extraction, gel electrophoresis and immunoblotting  
Histone H1 was purified with a 5% perchloric acid solution for 1 hour at 4ºC. Soluble 
acid proteins were precipitated with 30% trichloroacetic acid overnight at 4ºC, washed 
twice with 0.5 ml of acetone and reconstituted in water. Protein concentration was 
determined with the Micro BCA protein assay (Pierce). The purified histones were 
separated by 10% SDS-PAGE, transferred to a polyvinylidene difluoride (PVDF) 
membrane, blocked with Odyssey blocking buffer (LI-COR Biosciences) for 1 hour, 
and incubated with primary antibodies overnight at 4ºC and with secondary antibodies 
conjugated to fluorescent dye (IRDye 680 goat anti-rabbit IgG, Li-Cor) for 1 hour at 
room temperature. Then, the bands were visualized and quantified in an Odyssey 
Infrared Imaging System. All the polyclonal antibodies specifically recognizing human 
H1 PTMs that are described here were produced on request by Abcam or Millipore by 
rabbit immunizations with the peptides indicated in Table 1. Other antibodies used in 
this study, including histone H1 variant specific antibodies generated in our laboratory, 
are available from Abcam: H1.0 (ab11079), H1.2 (ab17677), H1.3 (ab24174), H1.5 
(ab24175), H1-T18P (ab3595), H1.4-T146P (ab3596), EZH2 (ab51605), Suv39H 
(ab12405), and HA (ab9110). Total H1 antibody was from Millipore (05-457). HP1ß 
was from Euromedex (1MOD-1A9-AS).  
2.4. Phosphatase treatment of H1 extracts 
Purified H1 histones were incubated for 30 min at 30ºC with recombinant Lambda 
Protein Phosphatase (New England BioLabs) at 5 to 100 Units in a 50-µl reaction 
volume containing 50 mM HEPES, 100 mM NaCl, 2 mM DTT, 0.01% Brij 35, pH 7.5 
and 1 mM MnCl2. The reaction was stopped by heat inactivation after the addition of 
gel electrophoresis loading buffer and H1 was resolved in SDS-PAGE for 
immunoblotting. 
2.5. Chromatin immunoprecipitation (ChIP) 
ChIP was performed according to the Upstate-Millipore standard protocol. Briefly, cells 
were fixed using 1% formaldehyde, harvested and sonicated to generate chromatin 
fragments between 200 and 500 bp. The sheared chromatin was immunoprecipitated 
overnight using 2 µg of antibody against HA. The immunocomplexes were recovered 
using a mix of protein A and protein G Sepharose, washed and eluted. The cross-linking 
was reversed at 65ºC overnight and immunoprecipitated DNA was recovered using the 
PCR Purification Kit from Qiagen. The presence of the genomic regions of interests 
was checked by real-time PCR, which was performed on ChIP and input DNA using 
EXPRESS SYBR GreenER qPCR SuperMix Universal (Invitrogen) and specific 
oligonucleotides in a Roche 480 LightCycler. ChIP values were corrected for their 
corresponding input chromatin sample. All oligonucleotide sequences used for the 
amplifications are available upon request. 
2.6. Immunoprecipitation 
Nuclear extracts were prepared by sonication of nuclei in 10 mM HEPES (pH 7.9), 2.25 
µM MgCl2, 20% (vol/vol) glycerol, 0.1 mM EDTA, 0.1% Nonidet P-40, 1 M NaCl. 
Supernatant was dialyzed in BC200 buffer: 25 mM Tris (pH 7.9), 10% (vol/vol) 
glycerol, 0.2 mM EDTA, 200 mM KCl). For immunoprecipitations, nuclear extracts 
adjusted to equal protein concentrations were incubated for 2 h with antibodies. Protein 
A beads were then added to the mixes, which were further incubated for 1 h. Beads 
were collected by centrifugation and washed three times in BC200 buffer. Proteins were 
eluted in 2x SDS sample buffer at 80°C for 10 min. 
2.7. Purification and infrared spectroscopy of human H1.2 and its mutants 
HA-tagged H1.2 and its mutants, T165A and T165E, were cloned into pEV21a 
generating histidine tagging, and these vectors transformed into E. coli BL21 (DE3). 
Recombinant proteins were expressed and purified by metal-affinity chromatography as 
previously described [37]. Then, the buffer was exchanged and the recombinant proteins 
were digested with carboxypeptidase A (Type II-PMSF treated) in the conditions 
specified by the manufacturer (Sigma) to remove the His6-tag. The proteins were further 
purified by hydroxyapatite chromatography on a CHT-II cartridge (Bio-Rad) as 
previously described [38]. Finally, the proteins were desalted by gel filtration through 
Sephadex G-25 (Amersham Biosciences) and lyophilized. FTIR spectra of human 
histone H1.2 and its mutants were measured at 5 mg/ml in 10 mM HEPES (pH 7.0) plus 
140 mM NaCl in D2O medium. Measurements were performed on an FT600 Bio-Rad 
spectrometer equipped with an MCT detector, using a demountable liquid cell with 
calcium fluoride windows and 50-μm spacers. Typically, 1000 scans were performed 
for each background and sample, and the spectra were obtained with a nominal 
resolution of 2 cm
-1
, at 22ºC. DNA-protein complexes contained the appropriate amount 
of DNA for each protein/DNA ratio (w/w). The DNA contribution to the spectra of the 
complexes with the H1.2 species was subtracted as described elsewhere [39]. Data 
treatment and band decomposition of the original amide I’ band were performed as 
previously described  using GRAMS 9.0 software [40]. 
2.8. RNA extraction, reverse transcriptase PCR and microarrays 
Total RNA was extracted using a High Pure RNA Isolation Kit (Roche) according to 
the manufacturer’s instructions, and the cDNA was obtained from 100 ng of total RNA 
using a SuperScript VILO cDNA synthesis Kit (Invitrogen). The real-time PCRs were 
performed using EXPRESS SYBR GreenER qPCR SuperMix Universal (Invitrogen) 
and specific oligonucleotides in a Roche 480 LightCycler. The procedures for 
microarray hybridization using an Illumina platform (GPL6883 Illumina HumanRef-8 
v3.0 Expression BeadChip) and data analysis are described elsewhere [7]. Gene 
ontology analysis was performed using the Gene Set Enrichment Analysis (GSEA) 
program. Microarray data sets are available in the Gene Expression Omnibus (GEO) 
database under the accession number GSE55786. 
3. RESULTS 
In order to study the dynamics of histone H1 PTMs in cultured human cells, we 
developed polyclonal antibodies specifically recognizing some of the H1 PTMs 
described elsewhere by mass spectrometry analysis [6,7] namely: K17 acetylation (K17-
Acet), K26 acetylation / S27 phosphorylation (K26-Acet/S27-P), K26 trimethylation / 
S27 phosphorylation (K26-Met/S27-P), K46 ubiquitination (K46-Ub), and T165 
phosphorylation (T165-P) (Table 1). All the antibodies were obtained by standard 
procedures and their specificities were evaluated by dot blot (see Supplementary data, 
S1).   
We analyzed the dynamics of these H1 PTMs using the T47D breast cancer cell line 
either untreated or treated with Colcemid to induce cell cycle arrest in mitosis. Histone 
H1 proteins were then extracted and analyzed by Western blot (Fig. 1). The level of H1 
acetylation on K17 decreased upon accumulation of cells in mitosis, while the adjacent 
CDK-mediated T18 phosphorylation increased. We established that the H1 variant 
specifically recognized by the K17-Acet antibody was H1.4 by immunoprecipitation of 
stably-expressed H1.4-HA followed by immunoblotting and by depletion of the 
endogenous H1.4 (see Supplementary data, S2A and B), in agreement with the peptide 
sequence used for generating this antibody. H1 ubiquitination on K46 also decreased 
during G2/M arrest and the signal almost disappeared upon knock-down of H1.5 
indicating that it may be the variant harboring this modification in cultured T47D cells, 
despite the peptide used for rabbit immunization being common to four somatic H1 
variants (Fig. 1) (see Supplementary data, S2C). 
Then, we analyzed phosphorylation on T165, which increased upon Colcemid-induced 
mitosis arrest (Fig. 1). T165 phosphorylation was specific for the H1.2 variant as shown 
by both immunoprecipitation of stably expressed H1.2-HA (Fig. 2A and Supplementary 
data, S3A), and depletion of the endogenous H1.2 (Fig. 2B). T165-P of H1.2 at mitosis 
was also seen in HeLa cells (Fig. 2C). Moreover, the antibody was specific for the 
phosphorylated residue as the hybridization signal disappeared upon phosphatase 
treatment of purified H1 (Fig. 2D and Supplementary data, S3B).  
Release of cultured cells from a double thymidine block revealed that H1.2 T165 
phosphorylation occurred parallel to phosphorylation of H1.4 T146, a known CDK 
target site (Fig. 3A). In HeLa cells, six hours after the double thymidine block release, 
most cells were in S phase, while T165 and T146 residues appeared to be 
phosphorylated and remained in this state when the cells moved to G2/M. In T47D 
cells, there was a low rate of transition to the S phase and the phosphorylation increased 
at eight hours coinciding with a peak in the number of cells in G2/M. This suggests that 
H1.2 T165 is phosphorylated during replication and mitosis, similar to other H1 
residues targeted by CDKs. Nonetheless, T165 is not within a CDK recognition motif 
and its phosphorylation was unaffected by the CDK inhibitor roscovitine (see 
Supplementary data, S4). The KinasePhos web tool [41] predicted T165 to be in a 
Protein Kinase C (PKC) recognition motif but T165-P was not affected by the PKC 
inhibitor GF109203X either. Similarly, it was unaltered by inhibitors of other candidate 
kinases, namely Aurora, PI3K, pTEF-b and PKA, it remaining unclear which enzyme is 
responsible for the phosphorylation in this case (see Supplementary data, S4 and data 
not shown). 
At this point, we have identified the presence of H1.2 T165 phosphorylation in breast 
(T47D) and cervical (HeLa) cancer cell lines. Next, we explored whether the 
phosphorylation of H1.2 T165 also occurred in several colon cancer cell lines and, if so, 
whether there were differences between cell lines derived from low- or high-grade 
cancers. T165-P was detected and was more intense in cells derived from high-grade 
cancers, similar to H1.4 T146-P (Fig. 3B). As high-grade cancer cells are more 
proliferative, this finding indicates that both modifications may serve as proliferation 
markers for cancer diagnosis. In addition, H1.3 was absent in the cell lines derived from 
higher-grade primary tumors, suggesting that not only PTMs but also H1 variants 
abundance may differ over the course of tumor progression. 
In order to investigate the dispensability of T165 and its phosphorylation, this residue 
was substituted by Ala and Glu within a stably expressing hemagglutinin-tagged H1.2 
(H1.2-HA) in T47D cells in order to inhibit or mimic this phosphorylation (H1.2-
T165A and H1.2-T165E), respectively (see Supplementary data, S5A). Mutations of 
this T165 residue had no apparent effect on proliferation and the cell cycle, on H1.2 
binding to chromatin (see Supplementary data, S5B-C), or on the global structure of the 
mutated proteins compared with the WT as judged by infrared spectroscopy on 
recombinant H1.2 in the presence or not of DNA (see Supplementary data, Table S1). 
As predicted, the T165-P antibody was unable to recognize H1.2-T165A, but 
constitutively recognized H1.2-T165E (see Supplementary data, S5D). ChIP of H1.2-
HA showed that this variant bound to active and repressed promoters, coding regions 
and satellite DNA with nearly no differences between the mutated and the WT forms of 
H1.2 (Fig. 4). Active genes (CDK2, JUN), but not repressed genes (NANOG), showed 
local H1.2 (WT or mutant) depletion at the transcription start sites (TSS) compared with 
the corresponding upstream promoter region, as described elsewhere [33,42]. 
Additionally, we designed several antibodies specifically recognizing the acetylated or 
trimethylated form of H1.4-K26, alone or in combination with H1.4-S27 
phosphorylation. The antibodies recognizing the K26-3Met and K26-Acet alone cannot 
detect these modifications when the adjacent serine (S27) is phosphorylated, as shown 
by dot blot analysis (see Supplementary data, S1). Conversely, the antibodies K26-
Met/S27-P and K26-Acet/S27-P can only detect K26 modifications in the presence of 
S27-P. Accordingly, Colcemid treatment, predicted to increase H1.4-S27 
phosphorylation, resulted in a lower level of detection of K26-3Met and K26-Acet by 
antibodies raised against these single modifications, whereas there was a higher level of 
detection with the antibodies against double modifications, suggesting a switch from 
mono- to bi-modified H1.4 K26-S27 residues (Fig. 1). 
Antibody binding decreased upon H1.4 knock-down in T47D and HeLa cells, as well as 
upon phosphatase treatment of purified H1, demonstrating its H1.4 variant and 
phospho-specificity (see Supplementary data, S6). The release of cultured T47D cells 
from a double thymidine block revealed that bi-modified K26-S27 increased at G2/M (8 
h after release), as did single S27 phosphorylation, while single K26 trimethylation 
decreased (Fig.5A and Supplementary data, S7). Interestingly, in HeLa cells K26-
Met/S27-P did not accumulate in S phase as occurred for H1.4 T146 and H1.2 T165 
phosphorylation (Fig. 3A). 
Considering the reported role of the H1.4-K26 residue in recruiting HP1 proteins, we 
then decided to mutate this residue and compare the growth of T47D cell lines stably 
expressing HA-tagged H1.4 WT with K26A. The H1.4-K26A mutation led to a 
decrease in cell proliferation compared with H1.4-WT expression, possibly due to 
G2/M arrest (Fig. 5B and C and Supplementary data, S8). In chromatin extracts, we 
verified that both H1.4-WT and K26A are equally well incorporated into chromatin 
(Fig. 5D). Interestingly, the presence of H1.4-K26A in chromatin was associated with 
lower levels of H1.4 partners which are known to bind this residue, i.e., HP1ß and 
EZH2 (Fig. 5D and Supplementary data, S9). Furthermore, the H1.4-K26A mutant was 
less well stabilized in heterochromatin satellite regions, as shown by ChIP (Fig. 5E and 
Supplementary data, S10).  
In order to investigate whether the potential modifications of H1.4-K26 play a role in 
gene expression control, we compared global gene expression of H1.4-WT and K26A 
over-expressing cell lines using microarrays. The expression of both proteins produced 
both up- and down-regulation of some genes compared with levels in control cells. 
Most genes deregulated upon H1.4-WT expression were also affected in K26A 
expressing cells, but around 19% depended on K26 integrity (Fig. 5F and 
Supplementary data, Table S2). Interestingly, K26A expression deregulated 
approximately twice as many genes as H1.4-WT, maybe due to the proliferation defect 
in K26A cells. In relation to this, ontology analysis of genes differentially expressed in 
H1.4-WT and K26A cells using the GSEA program revealed changes in biological 
functions related to the cell cycle and DNA metabolism (see Supplementary data, Table 
S3). Further evidence that H1.4 levels may influence gene expression came from the 
observation that some of the genes up- or down-regulated upon H1.4 overexpression 
were deregulated in the opposite sense upon H1.4 knockdown, mainly genes repressed 
by H1.4 such as CDC20B or ROPN1L (see Supplementary data, S11).  
To test if the genes found to be differentially expressed upon H1.4 expression that 
depended on K26 are normally enriched/depleted for H1.4 we took our ChIP-seq data 
on H1.4-HA distribution [42] and look at the number of enriched and depleted islands 
on those genes compared to random samples of the same number of genes (see 
Supplementary data, S12). Although up-regulated genes presented more H1.4 (and other 
H1 variants, data not shown) enrichment islands and less depletion islands than random 
genes, p-values indicated that this was not significant. Similarly, down-regulated genes 
presented non-significant reduced numbers of enrichment islands, but average number 
of depletion islands. In conclusion, no evidences yet point towards the notion that the 
subset of genes deregulated upon depletion or overexpression of a particular H1 variant 
are specifically enriched on such variant. 
4. DISCUSSION 
 
Depletion experiments of individual H1 variants in cultured cells have shown that 
distinct small subsets of genes are regulated by each variant and different phenotypes 
are produced [7]. Histone variant-specific PTMs could account for differential effects of 
the accumulation or depletion of distinct variants. Moreover, PTMs may be dynamic, 
adapting to cell cycle progression or responding to external stimuli or to the activation 
of a variety of signaling pathways. One of the consequences of the H1 variant PTMs 
may be an alteration of the interaction between histones and DNA, or between histones 
and chromatin-associated proteins. 
Post-translational modifications of core histones, in particular H3 and H4, have been 
extensively studied and are the basis for the so-called ‘histone code’ involved in the 
regulation of genome functions including gene expression control. By contrast, little is 
known about linker histone PTMs. Few modifications, mostly CDK-dependent Ser and 
Thr phosphorylations, were investigated before two reports described the identification 
of new histone H1 PTMs by mass spectrometry analysis [13,14]. The historical 
difficulty of obtaining good antibodies against H1 variants or their PTMs has left 
uninvestigated the occurrence and functional relevance of such PTMs. 
We have developed and tested polyclonal antibodies against several H1 PTMs including 
phosphorylation, acetylation, trimethylation and monoubiquitination, and also 
antibodies against double modifications (Lys-acetyl/Ser-phospho or Lys-trimethyl/Ser-
phospho). Here we show the results with the antibodies that are able to detect the 
occurrence of H1 PTMs in a breast cancer cell line. In addition to the PTMs described 
above, we also tested antibodies raised against the following modifications present in 
several H1 variants: K34, K46, K85 and K90 acetylations, K90 formylation, and the 
double modification K34-acet/S36-phospho (see Supplementary data, S13). Those 
raised against acetylated Lys were specific for the modified peptide and reacted with H1 
extracted from cells in Western blot experiments, but overall were not further 
characterized due to their low reactivity. 
We have focused on the dynamics, histone variant specificity and dispensability of two 
modified residues: H1.2 T165 phosphorylation and H1.4 K26 acetylation or 
trimethylation, and its interplay with phosphorylation of its neighbor S27. We show that 
phosphorylation of these amino acids occurs during the G2/M phase of the cell cycle. In 
fact, H1.4-S27 phosphorylation by Aurora B over the course of mitosis has been 
previously reported [24]. While the global increase in H1 phosphorylation during 
mitosis was expected, the decrease in K46-ubiquitination is more surprising and needs 
further investigation. Less K26 acetylation and trimethylation were also detected when 
cells accumulated in mitosis, presumably due to S27 phosphorylation of existing K26-
unmodified, acetylated or trimethylated histone H1.4, as the level of detection with the 
double-modification antibodies was higher. This indicates that the double modifications 
exist in vivo at the same histone tail at the same time, and that anti K26-acet or K26-
trimet antibodies are unable to recognize these modifications when a phosphate group is 
added to the neighboring Ser. Similarly, as proposed by the phospho-switch model, a 
protein binding to modified K26 may be released when S27 is phosphorylated [29]. 
Interestingly, T165-P started to accumulate in S phase, as previously reported for the 
CDK-dependent phosphorylation of histone H1 at (S/T)-P-X-(K/R) motifs, suggesting 
that this modification may have a more complex role than chromosome compaction 
during mitosis. H1 phosphorylation over the course of DNA replication has been 
implicated in chromatin decompaction. Our attempts to identify the kinase responsible 
for T165 phosphorylation have so far been unsuccessful. It would be interesting to 
determine which as yet unknown signaling pathways regulate this newly described 
phosphorylation on histone H1.2, as well as its biological relevance. One possibility 
could be that multiple kinases target H1.2 T165 redundantly. We have shown that T165-
P is dispensable for cell cycle progression and H1.2 binding to chromatin. This suggests 
that T165-P may be additive to the CDK-dependent phosphorylation of other Ser and 
Thr residues and by itself have limited structural consequences, instead of representing 
a highly specific regulatory binding site for a specific factor. Alternatively, T165-P may 
be dispensable for the cell type analyzed here grown under cell culture conditions or 
even completely non-functional, but may be more relevant under other conditions. 
On the other hand, here we suggest that K26 modifications are required for proper cell 
proliferation and stabilization of heterochromatin. The mutation of the H1.4-K26 
residue has a significant effect on the cell cycle and gene expression, probably due to a 
defect in the recruitment of histone H1 partners to chromatin. Expression of H1.4-K26A 
induced both up- and down-regulation of gene expression compared with H1.4-WT 
expression, consistent with both active and repressive effects of H1.4-K26 PTMs. Very 
few genes presented altered expression in opposite senses whether H1.4 was 
overexpressed or knocked down, and we do not believe that this is due to specific 
binding of H1.4 to these promoters, as we have previously reported that all gene 
promoters are bound by any H1 variant quite indistinctly [42]. We have shown here that 
a subset of genes differentially expressed upon H1.4 overexpression do not contain 
significant enrichment of this variant. Despite ubiquitous binding of H1 variants to 
promoters, differential interaction with partners, probably mediated by variant-specific 
PTMs, may explain specific participation of H1 variants to gene expression. 
We have proposed that phosphorylation of H1 residues such as T165 in H1.2 and T146 
in H1.4 may be considered proliferation markers and, accordingly, mark tumor cells 
with the highest rate of division, regularly associated with the highest level of 
malignancy. It is likely that cell cycle-dependent phosphorylation of certain Ser or Thr 
residues in the tails of H1 variants is of major importance in determining the 
architecture of chromatin during cell proliferation and differentiation. Alterations in the 
regulation of H1 phosphorylation may be involved in the genetic dysregulation that is 
fundamental to carcinogenesis. Aberrant chromatin structure may contribute to 
malignant transformation and tumor formation. Understanding the role of different H1 
variants and their modification profiles may be relevant to many aspects of cell survival, 
proliferation, apoptosis, differentiation and transformation. 
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FIGURE LEGENDS 
Figure 1. Histone H1 PTMs are dynamic over the cell cycle. Histone H1 was 
extracted from T47D cells treated or not with Colcemid (50 ng/ml) overnight, resolved 
in SDS-PAGE, and immunoblotted with antibodies specifically recognizing human 
H1.0 or histone H1 PTMs.  
Figure 2. The T165-P antibody is specific for H1.2. (A) Immunoblot of H1.2-T165-P 
after H1.2 immunoprecipitation. H1.2-HA was immunoprecipitated with an anti-HA 
antibody, or IgG as a control, from nuclear extracts of cells stably expressing H1.2-HA, 
and blotted with the indicated antibodies. (B) Immunoblot of H1.2-T165-P after H1.2 
depletion. T47D derivative cells stably infected with a lentiviral inducible system for 
the expression of shRNA against H1.2 (H1.2 KD) were treated for 6 days with 
doxycycline or left untreated. Colcemid was added 4 hours prior to H1 extraction where 
indicated. H1 extracts were analyzed by immunoblot against H1.2-T165-P, H1.2 or 
H1.5 as a loading control. (C) HeLa cells harboring the inducible shRNA against H1.2 
or a control random shRNA were treated and analyzed as in (B). Coomassie staining of 
H1 PAGE is shown as a loading control. (D) Immunoblot of H1.2-T165-P after 
phosphatase treatment. H1 was extracted from T47D cells treated or not with colcemid 
overnight, incubated with increasing concentrations of Lambda Protein Phosphatase for 
30 min and immunobloted with H1.2-T165-P antibody. Coomassie staining and H1.0 
immunoblot are shown as loading controls. 
Figure 3. H1.2 T165-P occurs at S and G2/M phases of the cell cycle and marks 
highly proliferative cancer cells. (A) Analysis of H1 phosphorylation after release 
from double-thymidine block. HeLa or T47D cells were arrested at the beginning of the 
S phase using a double thymidine block. After release for different times, cells were 
harvested to perform cell cycle analysis by fluorescence-activated cell sorting (FACS) 
after propidium iodide staining, and H1 extraction. Immunoblot was performed with the 
indicated H1 phospho-specific antibodies. H1.2 blotting and Coomassie staining were 
used as loading controls. Graphs with band density quantification are shown in 
Supplementary data, S7C. The upper graphs represent the percentage of cells in G1, S 
and G2/M phases as established by FACS. (B) H1.2 T165-P in colon cancer cell lines at 
different stages of malignancy. H1 was extracted from seven different colon cancer cell 
lines growing exponentially and immunoblotted against the indicated antibodies. Colon 
cancer cell lines are ordered by origin from high- to low-grade malignancy and 
proliferation rate. HCT116 (1; grade D), SW48 (2; grade IV), SW480 (3; grade III-IV), 
HCT15 (4; grade C), LS147T (5; grade B), LS180 (6; grade B), and Caco2 (7; grade I). 
Grades A to D (Dukes’ classification), or I to IV, from low to high malignancy, are 
indicated. Coomassie staining was used as loading control; notice that LS180 was 
overloaded. Relative band density quantification for each antibody respect to H1.2 
(Pearson’s R correlation coefficient between H1.2 and Coomassie was 0.95) and 
relative to the maximal value is shown on the right panels. 
Figure 4. The T165 residue is dispensable for proper H1.2 loading onto chromatin. 
Cross-linked chromatin from T47D cells stably expressing H1.2-HA WT, T165A or 
T165E was used for ChIP experiments with an anti-HA antibody or IgG as control. The 
precipitated DNA fragments were used for qPCR with primers for the indicated regions 
of CDK2, JUN and NANOG genes (upstream promoter, TSS and within the coding 
region), and for the repetitive satellite regions SAT2 and SATa. CDK2 and JUN 
represent active genes in T47D cells, while NANOG is repressed. The coding region of 
NANOG was not assessed. Amplification of input DNA (representing 1% of 
immunoprecipitated DNA) was used for normalization. The means and SDs are shown 
for a representative experiment quantified in triplicate. Significance between H1 mutant 
data sets was tested using the Student's t-test (* p-value<0.05; ** p-value<0.01; ns, no 
significance). 
Figure 5. The H1.4-K26 residue is required for proper cell proliferation and 
stabilization in heterochromatin. (A) H1.4 S27-P occurs at the G2/M phase of the cell 
cycle. T47D cells were arrested at the beginning of S phase using a double thymidine 
block. Upon release at different times, cells were harvested to perform cell cycle 
analysis by FACS after propidium iodide staining, and H1 extraction. Immunoblot was 
performed with the indicated H1.4 antibodies. H1.0 blotting was performed as a loading 
control. The upper graphs represent the percentage of cells in G1, S and G2/M phases as 
established by FACS. Graph with band density quantification is shown in 
Supplementary data, S7B. (B) Expression of H1.4-K26A impairs cell proliferation. 
Both H1.4-HA WT and K26A stably expressing cell lines (GFP-positive) were mixed 
1:1 with parental T47D cells (GFP-negative). Every three days, cells were split and the 
percentage of GFP-positive cells measured by fluorescence-activated cell sorting. Data 
are expressed as the ratio of GFP-positive versus GFP-negative cells over time and 
correspond to a representative experiment performed in duplicate. (C) K26A cells 
accumulate in G2/M. Cell cycle profile after propidium iodide (PI) staining of H1.4-HA 
WT and K26A expressing cells, represented as the percentage of cells in G1, S and 
G2/M. Data correspond to a representative experiment performed in duplicate. The 
means and SDs for four independent experiments are shown. Significance was tested 
using the Student's t-test (* p-value<0.05; ** p-value<0.01). (D) Chromatin content in 
H1.4-HA WT or K26A stably expressing cells. Chromatin was extracted from cells 
stably expressing H1.4-HA WT or K26A and analyzed by immunoblot with the 
indicated antibodies. Bands were quantified and the ratio between K26A and WT is 
indicated. (E) Detection of histone H1.4-HA WT or K26A at heterochromatic regions. 
Cross-linked chromatin from T47D cells stably expressing H1.4-HA WT or K26A was 
used for ChIP experiments with an anti-HA antibody. The precipitated DNA fragments 
were exposed to qPCR with primers for the indicated regions. Amplification of input 
DNA (representing 1% of immunoprecipitated DNA) was used for normalization. The 
means and SDs are shown from a representative experiment quantified in triplicate. 
Significance was tested using the Student's t-test (** p-value<0.01). (F) Expression of 
H1.4-HA WT and K26A deregulates common and unique genes. Venn diagrams 
showing the number of genes up- or down-regulated with a fold change (FC) ≥1.4 in 
H1.4-HA WT or K26A expressing cells compared to control cells established by 
Illumina microarray hybridization. 
 
Table 1. Antibodies recognizing histone H1 post-translational modifications. 
  
PTM 
H1 variant  
Immunizing peptide 
H1 variant  
Source 
Catalog 
no. 
Addit. 
PTMs3 (PTM)1 (peptide)2 
K17 acetyl 2, 3, 4, 5 AAPAPAE(acK)TP 4 Millipore NA T18ph 
K26 acetyl 4 AR(acK)SAGAAKRK 4 Millipore NA 
S27ph, 
K34ac 
K26 trimethyl 4 
VKKKAR(3meK)SAG
AA 
4 Abcam NA S27ph 
S27 phospho 4 VKKKARK(pS)AGAA 4 Abcam NA K26me/ac 
K26 acetyl / S27 
phospho 
4 
AR(acK)(pS)AGAAKR
K 
4 Millipore 06-1372 K34ac 
K26 trimethyl / S27 
phospho 
4 
VKKKAR(3meK)(pS)A
GAA 
4 Abcam ab33231 – 
K46 ubiquitin 2, 3, 4 IT(ubK)AVAASK 2, 3, 4, 5 Millipore NA K52ac 
T165 phospho 2 AA(pT)VTKKVAK 2 Millipore 06-1370 K168ac 
1 H1 variants where the indicated PTM has been described in the Garcia et al. or Wisniewski et al. reports. 
2 H1 variants where the designed immunizing peptides share 100% sequence identity. 
3 Residues present in the immunizing peptides that can receive additional PTMs according to the reports 
indicated above. 
 
NA, not currently available. 
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